By continuing to use our site, you agree to our Terms of Use and Privacy Policy. You can learn more about how we use cookies by reviewing our Privacy Policy.

I Agree

About Eugene P. Kennedy, MD, FACS:

Eugene P. Kennedy, MD, FACS, has served as Lumos Pharma and previously NewLink Genetics CMO since November 2017. Prior to that, he served as Vice President for Clinical and Medical Affairs since 2014, having joined NewLink in 2013. With NewLink, Dr. Kennedy has been responsible for the design, implementation, and execution of more than a dozen clinical trials ranging from multiple first in human studies through Phase 3 while overseeing a total of more than 20 studies across 11 product candidates in addition to multiple investigator-initiated efforts.

Prior to joining NewLink Genetics, Dr. Kennedy was on faculty and clinical staff at Thomas Jefferson University in Philadelphia, PA where he served as Associate Professor of Surgery. During his time at Jefferson, he built a clinical and translational research program focused on the treatment of pancreatic cancer, launching both internally and externally sponsored trials while building the infrastructure to support both. Dr. Kennedy held leadership positions as Chief of the Section of Pancreaticobiliary Surgery and Co-Director of the Jefferson Pancreas, Biliary, and Related Cancers Center from January 2006 to December 2013. He served the institution as the Chair of the Data Safety Monitoring Committee for the Sidney Kimmel Cancer Center at Jefferson in addition to other positions and his patient care and teaching responsibilities. Previously, Dr. Kennedy held faculty appointments at the Johns Hopkins Hospital in Baltimore, MD and the Louisiana State University School of Medicine in New Orleans, LA.

Dr. Kennedy received a B.A. degree as an Echols Scholar from the University of Virginia in Charlottesville, VA and a M.D. degree with honors (Alpha Omega Alpha) from the Medical College of Virginia in Richmond, VA. He obtained his General Surgical residency and Surgical Oncology fellowship training at the Johns Hopkins School of Medicine in Baltimore, MD along with a post-doctoral fellowship in immuno-oncology at Johns Hopkins and surgical training at the Royal College of Surgeons in Ireland School of Medicine Beaumont Hospital in Dublin, Ireland. He has over 50 peer-reviewed publications as well as numerous book chapters, reviews, and abstracts.

Dr. Kennedy has served for over 10 years as a Trustee of the Hope Funds for Cancer Research whose mission is focused on the investigation of innovative cancer treatment and detection for the most difficult-to-treat and understudied cancers.